MAPT and Alzheimer disease: GSK3 includes GSK3α and GSK3-β, of which GSK3-β is considered a key participant in AD pathophysiology, and imbalances in the kinase affect the hyperphosphorylation of tau protein, cognitive impairment, neurogenesis, synaptic function, and apoptosis induced by Aβ over deposition [13, 14].